ELKINS SINN
GenericsELKINS SINN is a generic drug manufacturer focused on Cardiovascular, Gastroenterology, Infectious Disease.
ELKINS SINN's Key Drugs
ELKINS SINN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ELKINS SINN's Recent FDA Approvals
New NDA/BLA approvals for ELKINS SINN over the last two years — novel drugs only, excluding generics and label supplements.
ELKINS SINN's Therapeutic Areas
ELKINS SINN's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ELKINS SINN's Top Competitors
ELKINS SINN's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ELKINS SINN Pipeline Snapshot
Active clinical trials for ELKINS SINN across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1946-08-13
- Latest
- 2001-09-10
- Applications
- 36